Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05695924

Surgical Evaluation for Upper Extremity Lymphedema (BioBridge)

Prospective Evaluation of Nanofibrillar Collagen Scaffold (BioBridge®) as an Adjunct to Lymph Node Transplant for Upper Extremity Lymphedema

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
60 (estimated)
Sponsor
Fibralign Corporation · Industry
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

To investigate whether the addition of Fibralign's BioBridge® Collagen Matrix (BioBridge) devices to the standard surgery for vascularized lymph node transfer will improve the outcome of surgical treatment in lymphedema of the upper arm.

Detailed description

The proposed study utilizes Fibralign's BioBridge® Collagen Matrix (BioBridge), a sterile implantable biocompatible and biodegradable surgical mesh ribbon comprised of highly purified porcine collagen. The Class II device was cleared by CDRH Division of Surgical Devices on 8 January 2016 under 510(k) K151083. The study will investigate whether addition of the BioBridge Collagen Matrix to the standard surgery for vascularized lymph node transfer will improve the outcome of surgical treatment in lymphedema of the upper extremity. This clinical study will also be used in support of IDE G200200 review conducted by the FDA. Primary endpoint is the post surgical % change in excess limb volume, measured at 12 months following the surgical procedure. Secondary endpoints are change in quality of life scores measured by LLIS and change in lymphatic function as measured by indocyanine green (ICG) fluorescence imaging.

Conditions

Interventions

TypeNameDescription
DEVICEBioBridge® Collagen MatrixBioBridge Collagen Matrix (BioBridge) is a sterile implantable bio-compatible and biodegradable surgical mesh ribbon comprised of highly purified porcine collagen. The Class II device was cleared by CDRH Division of Surgical Devices on 8 January 2016 under 510(k) K151083. The device will be used for soft tissue surgical support at the time of vascularized lymph node transplant surgery (VLNT); the device will be used, specifically, for surgical support of the lymphatic component of the soft tissue.
PROCEDUREVascularized Lymph Node Transfer (VLNT)Micro-surgical procedure for vascularized lymph node transfer (VLNT)

Timeline

Start date
2023-11-01
Primary completion
2025-10-01
Completion
2025-12-01
First posted
2023-01-25
Last updated
2025-03-11

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT05695924. Inclusion in this directory is not an endorsement.